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Background: Positive nodal status (pN1) is an independent predictor of survival in 
renal cell carcinoma (RCC) patients. However, no study to date has tested whether the 
location of lymph node (LN) metastases does affect oncologic outcomes in a population 
submitted to radical nephrectomy (RN) and extended lymph node dissection (eLND).
Objective: To describe nodal disease dissemination in clear cell RCC (ccRCC) patients 
and to assess the effect of the anatomical sites and the number of nodal areas affected 
on cancer specific mortality (CSM).
Design, setting and partecipants: The study included 415 patients who underwent RN 
and eLND, defined as the removal of hilar, side-specific (pre/paraaortic or pre/paracaval) 
and interaortocaval LNs for ccRCC, at two institutions.
Outcome measurement and statistical analysis: Descriptive statistics were used to 
depict nodal dissemination in pN1 patients, stratified according to nodal site and number 
of involved areas. Multivariable Cox regression analyses and Kaplan-Meier curves were 
used to explore the relationship between pN1 disease features and survival outcomes.
results and limitations: Median number of removed LN was 14 (IQR 9–19); 23% 
of patients were pN1. Among patients with one involved nodal site, 54 and 26% of 
patients were positive only in side-specific and interaortocaval station, respectively. The 
most frequent nodal site was the interaortocaval and side-specific one, for right and left 
ccRCC, respectively. Interaortocaval nodal positivity (HR 2.3, CI 95%: 1.3–3.9, p < 0.01) 
represented an independent predictor of CSM.
conclusions: When ccRCC patient harbour nodal disease, its spreading can occur at 
any nodal station without involving the others. The presence of interoartocaval positive 
nodes does affect oncologic outcomes.
Patient summary: Lymph node invasion in patients with clear cell renal cell carcinoma 
is not following a fixed anatomical pattern. An extended lymph node dissection, during 
treatment for primary kidney tumour, would aid patient risk stratification and multimodality 
upfront treatment.
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inTrODucTiOn
Positive nodal status and number of positive nodes are independent 
predictors of survival in renal cell carcinoma (RCC) patients (1, 2). 
Moreover, the role of lymph node dissection (LND) for RCC staging 
is widely accepted in intermediate/high risk patients, although its 
effect on cancer control is limited, especially in low risk patients 
(3). Adequate nodal staging and subsequent prognosis assessment 
become even more important in the light of the recent data 
published in the setting of adjuvant therapy, follow-up and salvage 
therapy (4–6).
The natural history of patients with nodal metastases is already 
known. Recently, it has been reported a 12% metastasis-free survival 
at 5 years (7). However, no study evaluated if prognosis is affected by 
location of the nodal metastasis or by the number of areas affected by 
nodal disease. This appears of paramount importance, if we consider 
that nodal invasion is often considered a criterion to define a RCC 
patient as metastatic, especially among medical oncologists.
Cadaveric dissection and sentinel-node studies (8–10) 
demonstrated wide heterogeneity of retroperitoneal lymphatic vessels 
anatomy. In addition, RCC histologies have different distant spreading 
rates (11) and oncologic outcomes (12, 13). Therefore, a critical 
analysis of nodal involvement areas in RCC patients submitted to RN 
and extended LND (eLND) might provide additional information on 
the pattern of lymphatic dissemination and its impact on the natural 
history of the disease.
Under such premises, the aim of this study was to describe 
nodal disease dissemination in clear cell RCC (ccRCC) 
patients and to assess the effect of the anatomical sites and the 
number of nodal areas affected by disease on cancer specific 
mortality (CSM).
MaTerials anD MeThODs
Patient Population
After institutional ethic committee board approvals (IRCCS San 
Raffaele, Milan and Ospedale Maggiore della Carita´, Novara, 
Italy), we identified 2,884 patients with sporadic, unilateral, RCC 
treated with open radical nephrectomy (RN) between 1980 and 
2012. Of these, 415 patients (14.4%) presented with clear cell 
RCC (ccRCC) histology and underwent RN plus eLND  (San 
Raffaele 165/415, 40% and Novara 250/415, 60%), defined by 
a template including hilar, side-specific (pre/paraaortic or pre/
paracaval) and interaortocaval nodal stations. All patients signed 
written informed consent to undergo surgery and to use clinical 
data in an anonymous fashion for scientific purposes. Nodal 
dissection template was shared between the Institutions, and 
ipsilateral template on the left side included nodes from the 
crus of the diaphragm to the inferior mesenteric artery, and 
on the right side, from the adrenal vein to the level of inferior 
mesenteric artery. Each nodal station was separately labelled 
and delivered to pathology (Figure 1).
The decision to perform LND was based on surgeon’s discretion 
and inclusion criteria were represented by cT2 disease and above, 
tumor size >10 cm, lymphadenopathies and palpable lymph 
nodes during surgery.
Outcomes
Outcomes were other cause mortality (OCM)- and cancer specific 
mortality (CSM)-free survival rate. Secondly, a description of the 
pattern of nodal cancer dissemination in pN1 patient was performed 
on the overall ccRCC population and after stratification according to 
the kidney tumour side (right vs. left). Finally, we assessed the CSM-
free survival rate according to the pattern of nodal dissemination 
(lymph node site or number of lymph node areas involved).
covariates
Covariates consisted of age, gender, tumour side (right vs. left), 
symptoms, clinical metastatic status (cM0 vs. cM1), pathological 
T stage (defined according to 7th American Joint Committee on 
Cancer classification) (14), pathological N stage, Fuhrman grade 
(according to the WHO/International Society of Urological Pathology 
classification) (15), tumour size, mean number of lymph nodes 
removed, number of positive lymph nodes, number of involved nodal 
sites, hilar, side-specific and interaortocaval nodal status.
statistical analyses
Statistical analyses, as well as reporting and interpretation of the 
results, consisted of three steps.
Firstly, means, medians and interquartile ranges or frequencies and 
proportions were reported for continuous or categorical variables on 
the study population, respectively. Kaplan-Meier analyses were used 
to assess OCM- and CSM-free survival rate at different time points, 
on the overall population and after stratification for pN status.
Secondly, among patients with pN1 disease, a description of 
anatomical nodal involvement, stratified according to the number 
of the involved nodal sites (1 vs. 2 vs. 3) was performed.
Figure 1 |  Sketch of left and right nodal templates (left template in red and 
right template in blue), adapted from (2).
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Thirdly, among patients with pN1 disease, Cox multivariable 
regression analysis was used to predict the risk of CSM. 
Predictors consisted of number of involved lymph node areas, 
age, pT stage, pathologic tumour size, Fuhrman grade, and 
cM status. In an additional set of Cox multivariable regression 
analysis predicting CSM, anatomical nodal involvement (hilar 
vs. side-specific vs. interaortocaval nodal invasion) was used 
instead of number of involved lymph node areas. All statistical 
tests were performed using RStudio graphical interface v.0.98 
for R software environment v.3.0.2 (R Foundation, Vienna, 
Austria). All tests were two-sided with a significance level set at 
p value < 0.05.
resulTs
Clinicopathologic features are summarized in Table 1. The median 
number of removed lymph nodes (LNs) was 14 (IQR 9–19) and the 
median number of positive LNs was 3 (IQR 2–8). Overall, 74 patients 
(18%) and 179 patients (43%) had systemic and local symptoms, 
respectively. Clinical M1 status was present in 112 patients (27%), 
pT3/pT4 disease was found in 260 patients (63%), while 199 (48%) 
had Fuhrman grade 3/4.
Median follow-up among survivors was 43.7 months, with an 
overall OCM- and CSM-free survival rate of 91 and 60%. The 1 year, 
3 year and 5 year OCM- and CSM-free survival rates were 97%, 93%, 
90% and 80%, 61%, 55%, respectively. When patients were stratified 
according to nodal status (namely, pN0 and pN1), pN0 patients had 
1 year, 3 year and 5 year CSM-free survival rates of 89, 72 and 66%, 
conversely pN1 patients’ CSM-free survival rates were 53, 20 and 
9% (p < 0.01; Figure 2). Median time to CSM in pN0 cM0 patients 
was 30 months.
Locations of nodal metastases are summarized in Figure 3 
and Table S1. Overall, within the group of patients with one 
positive nodal area, in 54% of patients metastatic dissemination 
skipped the hilar nodal area, while in 26% of cases, both the 
hilar and the side-specific areas were eluded. Instead, when 
looking at patients with two nodal areas involved, hilar nodal 
area was skipped in 54% of patients and side-specific area only 
in 4% of cases. Moreover after stratification for the ccRCC 
side, in case of interaortocaval-only nodal positivity among 
patients with one positive nodal site, 10 out of 12 patients 
had right ccRCC. This discrepancy was also identified in case 
of patients with two positive nodal areas and interaortocaval 
nodal involvement: the majority of patients had right ccRCC 
(14 out of 15 patients).
On Multivariable Cox regression analyses, when considering the 
location of nodal metastases, independent predictors of CSM were 
represented by pT3 (HR: 2.7; CI 95%: 1.5–5) and pT4 stage (HR: 6.1; 
CI 95%: 2.6–14.3), cM1 status (HR: 4.3; CI 95%: 3–6.2) and positive 
status of interaortocaval nodal area (HR: 2.3, CI 95%: 1.3–3.9), all 
p ≤ 0.01 (Table 2). Instead, when predicting CSM considering the 
number of positive nodal areas, independent predictors were pT3 
(HR: 2.6; CI 95%: 1.4–4.8) and pT4 stage (HR: 4.2; CI 95%:1.9–9.6), 
pathologic tumour size (HR: 1.1; CI 95%: 1–1.1), cM1 status (HR: 4.2; 
TaBle 1 |  Descriptive statistics of 415 patients submitted to radical 
nephrectomy and extended LND with clear cell renal cell carcinoma.
Variable Overall
Mean age (years; median, iQr) 57.6 (59, 55–66)
gender
Male 285 (68.7%)
Female 130 (31.3%)
symptoms
No symptoms 162 (39.0%)
Local symptoms 179 (43%)
Systemic symptoms 74 (18%)
site of primary tumour
Right 238 (57.3%)
Left 177 (42.7 %)
Decade of surgery
1980–1989 108 (26%)
1990–1999 202 (48.7%)
2000–2009 80 (19.3%)
2010–2012 25 (6%)
Metastatic status at diagnosis
cM0 303 (73%)
cM1 112 (27%)
Pathologic T stage
T1a 26 (6.3%)
T1b 74 (17.8%)
T2a 43 (10.4%)
T2b 12 (2.9%)
T3a 100 (24.1%)
T3b 105 (25.3%)
T3c 28 (6.7%)
T4 27 (6.5%)
Pathologic n stage
pN0 320 (77%)
pN1 95 (23%)
Fuhrman grade
1 20 (4.8%)
2 174 (41.9%)
3 162 (39.0%)
4 37 (8.9%)
NA 22 (5.3%)
Mean pathologic tumour size (cm; median, iQr) 9 (8.5, 6–11.5)
Mean number of nodes removed (median, iQr) 15 (14, 9–19)
Mean number of negative nodes (median, iQr) 13 (12, 7–17)
Mean number of positive nodes (median, iQr) 5 (3, 2–8)
hilar nodal status
Negative 371 (89.4%)
Positive 44 (10.6%)
side-specific (paraaortic/pre- or paracaval) nodal 
status
Negative 342 (82.4%)
Positive 73 (17.6%)
interaortocaval nodal status
Negative 365 (88%)
Positive 50 (12%)
number of nodal sites involved
0 320 (77%)
1 46 (11.2%)
2 26 (6.3%)
3 23 (5.5%)
Mean time to last follow-up or death (months; 
median, iQr)
75.6 (43.7,  
12.8–117)
4 March  2018 | Volume 5 | Article 26Frontiers in Surgery | www. frontiersin. org
Nini et al. Nodal Involvement and ccRCC
CI 95%: 2.9–6) and presence of any number of nodal area involved 
(HR: 1.6–2.7; CI 95%: 1–5), all p < 0.05 (Table 3).
However when considering only pN1 patients, no difference was 
seen at Kaplan-Meier analysis in terms of CSM-free survival rate, after 
stratification of number of involved nodal areas (p = 0.5; Figure 4).
DiscussiOn
Patients with nodal involvement in RCC have an 7.8-fold greater 
chance of CSM compared to pN0 counterparts (16, 17) and 
this has an independent prognostic value even in patient with 
metastatic RCC (1). Published retrospective studies (18) have 
indeed failed to reach an agreement on the topic. Moreover, the 
EORTC 30881 (19) did not demonstrate any benefit in terms 
of cancer control. Nevertheless, today, roughly 70% of that 
study population would have been classified as cT1abN0M0. 
In this regards, a subanalysis focusing only on cT3 tumours, 
showed a 15% overall survival benefit at 5 years for LND 
recipients (20). Therefore, EAU guidelines recognize the role 
of LND for cN1, although its extent remains controversial, and 
suggest an eLND for cN0 patients, only in presence of adverse 
clinical features (21). However, the picture appears even more 
complex, when considering that RCC histologies can differ 
in terms of distant spreading rates (11, 12) and oncologic 
outcomes (13).
Several observations of the current study are of importance. 
First, we described the oncologic outcomes of eLND in ccRCC 
patients. Cancer-specific mortality-free survival rates were worse 
for pN1 patients at any time point, compared to pN0 ones. 
According to Blute et al., among ccRCC patients, estimated CSM-
free survival rates at 1-, 5- and 10 year follow-up were 95, 82 and 
72.5% for pNx/pN0 patients and 52, 21 and 11% for pN +patients 
(16). Discrepancies with our results could be ascribed to inclusion 
of only cM0 ccRCC population and to omission of LND in some 
patients (42% of the overall population, data not shown for ccRCC 
histology). Moreover the study lacked of a definition for the extent 
of LND.
Figure 2 |  Kaplan-Meier depicting CSM-free survival rate on the overall population after stratification for the pN status (p-value < 0.01). Blue line: pN0 patients; 
Green line: pN1 patients.
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Second, for 54% of pN1 patients, disease eluded hilar nodal 
site (when considering patients with one or two positive nodal 
stations), in line with what has been previously reported by EAU 
guidelines (35–45%) (21). Only among patients with one positive 
nodal station, in 26% of patients, cancer skipped the hilar and 
the side-specific nodal stations. When looking at any patient 
with positive interaortocaval nodal station, the majority of them 
(n = 27/36, 75%) showed a right ccRCC. Focusing on those 
patients, with interaortocaval-only positive location of nodal 
metastases, 10/12 (83%) had right ccRCC. This observation is 
TaBle 2 |  Cox Logistic Regression analysis predicting CSM considering the location of nodal metastases.
uniVariaBle analYses MulTiVariaBle analYses
VariaBles hr (ci 95%) p-value hr (ci 95%) p-value
Positive hilar nodes 4.1 (2.7–6) <0.01 1.0 (0.6–1.8) 0.8
Positive side-specific nodes 4.2 (3–5.8) <0.01 1 (0.6–1.6) 0.9
Positive interaortocaval nodes 5 (3.4–7.3) <0.01 2.3 (1.3–3.9) <0.01
Age 1 (0.9–1) 0.9 1 (0.9–1) 0.2
pT stage pT2 vs. pT1 1.8 (0.9–3.5) 0.09 1.2 (0.6–2.5) 0.6
pT3 vs. pT1 5.6 (3.4–9.3) <0.01 2.7 (1.5–5) 0.01
pT4 vs pT1 21.6 (11.4–40.8) <0.01 6.1 (2.6–14.3) <0.01
Pathologic tumour size 1.1 (1.1–1.2) <0.01 1 (1–1.1) <0.01
Fuhrman grade 2.9 (2.1–4) <0.01 1.2 (0.9–1.8) 0.2
Clinical metastatic status 7.5 (5.5–10.2) <0.01 4.3 (3–6.2) <0.01
Figure 3 |  Nodal metastatic dissemination in the overall population and after stratification for the kidney site according to nodal areas and number of areas 
involved.
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line with the studies investigating the role of sentinel LND (9, 10). 
In the first paper, 7/14 patients presented with interaortocaval 
nodal positivity: 3 of them had interoaortocaval and side-specific 
nodal positivity, 2 interaortocaval-only nodal positivity and 2 
interaortocaval positivity and non-regional positivity; 6 of these 
patients had right kidney tumour. In the second, it was reported 
that right-sided tumour drained only to the paracaval nodes and 
left-sided tumours drained to the side-specific nodes.
It was formerly believed that RCC nodal drainage followed a fixed 
pattern, originating from the hilar region and branching off into the 
TaBle 3 |  Cox Regression analysis predicting CSM considering the number of locations of nodal metastases.
uniVariaBle analYses MulTiVariaBle analYses
VariaBles hr (ci 95%) p-value hr (ci 95%) p-value
Number of positive sites
1 vs. 0 4.5 (3–6.7) <0.01 1.6 (1–2.6) <0.05
2 vs. 0 5.3 (3.3–8.7) <0.01 1.7 (1–3) <0.05
3 vs. 0 6.5 (3.7–11.4) <0.01 2.7 (1.5–5) <0.01
Age 1 (0.9–1) 0.9 1 (0.9–1) 0.2
pT stage
pT2 vs. pT1 1.8 (0.9–3.5) 0.09 1.2 (0.5–2.4) 0.7
pT3 vs. pT1 5.6 (3.4–9.3) <0.01 2.6 (1.4–4.8) <0.01
pT4 vs. pT1 21.6 (11.4–40.8) <0.01 4.2 (1.9–9.6) <0.01
Pathologic tumour size 1.1 (1.1–1.2) <0.01 1.1 (1–1.1) <0.01
Fuhrman grade 2.9 (2.1–4) <0.01 1.2 (0.9–1.8) 0.2
Clinical metastatic status 7.5 (5.5–10.2) <0.01 4.2 (2.9–6) <0.01
Figure 4 |  Kaplan-Meier depicting CSM-free survival rate only in pN+ patients after stratification for the number of locations of nodal metastases (p = 0.5). Blue 
line: 1 positive nodal site; Green line: 2 positive nodal sites; Grey line: 3 positive nodal sites.
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cOnclusiOn
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independent predictor of CSM.
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